Georgiamune
Regulating signaling pathways to restore immune balance and fight cancer and autoimmune diseases, utilizing first-in-class assets with a robust pipeline of immunomodulators.
Employees
Enterprise value
$300—450m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
* | $75.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads